Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
NHS Launches OCT Scans for Diabetic Eye Care
The National Health Service (NHS) England is launching a nationwide program to make optical coherence tomography (OCT) scans more accessible, aiming to improve outcomes for patients with diabetic retinopathy. This initiative will bring advanced imaging technology closer to home for…
Ocular Pain in DED: Insights from the Tibetan Plateau
A recent Chinese study has shed light on the prevalence and influencing factors of ocular pain in individuals suffering from dry eye disease (DED) residing at high altitudes on the Tibetan Plateau. Co-authored by Peng-Cheng Zhang, MD, PhD, and Wen-Shan…
CHMP Endorses FYB203: Aflibercept Biosimilar Approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept. This development marks a significant milestone in expanding affordable…
USC Receives $6M Grant for Dry AMD Therapy
The California Institute for Regenerative Medicine (CIRM) has awarded a $6 million, two-year grant to researchers at the USC Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute. This funding will advance preclinical studies…
Adverum Shares Positive Ixo-vec Results for Wet AMD
Adverum Biotechnologies has released promising 52-week topline results from its Phase 2 LUNA trial and new 4-year data from the Phase 1/2 OPTIC study for its gene therapy candidate Ixo-vec (AAV.7m8-aflibercept), targeting wet age-related macular degeneration (AMD). Transformative Potential of…
EO2002: Non-Surgical Solution for Corneal Edema
Emmecell has announced positive results from its U.S. multicenter Phase 1 trial evaluating EO2002, an innovative non-surgical cell therapy for corneal edema. The randomized, double-masked trial demonstrated significant improvements in best corrected visual acuity (BCVA) and reductions in central corneal…
Ocugen Shares Positive OCU410 Trial Results for GA
Ocugen has released encouraging preliminary findings from the Phase 1 portion of its Phase 1/2 OCU410 ArMaDa clinical trial, focused on treating geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The results demonstrate the potential of OCU410 as…
FDA Awards Designations to Gildeuretinol for Stargardt
Key Takeaways • Gildeuretinol (ALK-001) has received Rare Pediatric Disease and Fast Track designations, alongside prior Breakthrough Therapy and Orphan Drug statuses, emphasizing its potential to transform treatment for Stargardt disease. • Data from the TEASE-1…
Ray Tracing Optimization – Myopic LASIK & AI
Laser-assisted in situ keratomileusis (LASIK) has become one of the most effective and safe methods for correcting refractive error with laser corneal intervention, as evidenced by the long and large number of publications in the peer-reviewed literature. In recent years,…
EC Approves Opuviz, Eylea Biosimilar
Samsung Bioepis and Biogen have announced that the European Commission (EC) has approved Opuviz 40 mg/mL for injection. This biosimilar, also known as SB15, references the widely used treatment Eylea (aflibercept). The approval encompasses a range of retinal conditions, providing…